Galera Therapeutics, Inc.

Galera Therapeutics, Inc. (GRTX) priced its initial public offering on Nov 8, 2019 at $12.00 per share, below its $14.00–$16.00 range, raising $60M, and listed on Nasdaq Global Market. At the IPO price its market capitalization was about $292.3M. BofA Securities was lead-left underwriter, joined by Citigroup, Credit Suisse and BTIG. Latham & Watkins advised the company and A&O Shearman advised the underwriters.

Galera Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing drugs based on superoxide dismutase mimetics to reduce normal tissue toxicity from radiotherapy in cancer. Its lead candidate, GC4419, is in a Phase 3 trial for severe oral mucositis in head and neck cancer patients and has FDA Breakthrough Therapy Designation.

Status

IPO

Ticker

GRTX

Exchange

Nasdaq Global Market

Priced

Nov 8, 2019

IPO price

$12.00

Price range

$14.00–$16.00

Raised

$60M

Market cap at IPO price

$292.3M

First filed

Oct 11, 2019

Underwriters

BofA Securities, Citigroup, Credit Suisse and BTIG

Company counsel

Latham & Watkins

Underwriters' counsel

A&O Shearman

Sector

Biotech & pharma

Country / state

PA

Market cap at IPO price = shares outstanding after the offering (all classes, before the over-allotment option) × the IPO price, from the final prospectus.